Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.37 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29249583 | 0.98 | FDPS (0.39) | FDPSGGPS1 | |
| SCHEMBL7377050 | 0.98 | FDPS (0.39) | FDPSGGPS1 | |
| SCHEMBL9539593 | 0.98 | FDPS (0.39) | FDPSGGPS1 | |
| SCHEMBL3051949 | 0.89 | CYP1A2 (0.48) | — | |
| SCHEMBL27982050 | 0.81 | FAAH (0.46) | — | |
| SCHEMBL28389005 | 0.81 | FAAH (0.46) | — | |
| SCHEMBL28181658 | 0.80 | FDPS (0.33) | FDPSGGPS1 | |
| SCHEMBL29526847 | 0.78 | FDPS (0.35) | FDPSGGPS1 | |
| SCHEMBL28159354 | 0.78 | FDPS (0.35) | FDPSGGPS1 | |
| SCHEMBL8909433 | 0.76 | CYP2C19 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0287652-B1 | SERUM-FREE MEDIUM FOR THE PROLIFERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS | LIFE TECHNOLOGIES INC (US) | 1994-01-12 | — | — | EP | claimed |
| EP-0287652-A4 | SERUM-FREE MEDIUM FOR THE PROLIFERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS. | LIFE TECHNOLOGIES INC (US) | 1990-01-08 | — | — | EP | claimed |
| EP-0287652-A1 | SERUM-FREE MEDIUM FOR THE PROLIFERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS. | LIFE TECHNOLOGIES INC (US) | 1988-10-26 | — | — | EP | claimed |
| WO-1988002774-A1 | SERUM-FREE MEDIUM FOR THE PROLIFERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS | LIFE TECHNOLOGIES, INC. (US) | 1988-04-21 | — | — | WO | claimed |
| US-7635798-B2 | Nucleic acid compositions conferring altered metabolic characteristics | DOW AGROSCIENCES, LLC (US) | 2009-12-22 | — | — | US | disclosed |
| US-20050091708-A1 | Nucleic acid compositions conferring altered metabolic characteristics | DOW AGROSCIENCES LLC | 2005-04-28 | — | — | US | disclosed |
| WO-2003020936-A1 | NUCLEIC ACID COMPOSITIONS CONFERRING ALTERED METABOLIC CHARACTERISTICS | THE DOW CHEMICAL COMPANY (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-0287652-B1 | SERUM-FREE MEDIUM FOR THE PROLIFERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS | LIFE TECHNOLOGIES INC (US) | 1994-01-12 | — | — | EP | disclosed |
| EP-0287652-A4 | SERUM-FREE MEDIUM FOR THE PROLIFERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS. | LIFE TECHNOLOGIES INC (US) | 1990-01-08 | — | — | EP | disclosed |
| EP-0287652-A1 | SERUM-FREE MEDIUM FOR THE PROLIFERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS. | LIFE TECHNOLOGIES INC (US) | 1988-10-26 | — | — | EP | disclosed |
| WO-1988002774-A1 | SERUM-FREE MEDIUM FOR THE PROLIFERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS | LIFE TECHNOLOGIES, INC. (US) | 1988-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050091708-A1 | Nucleic acid compositions conferring altered metabolic characteristics | FADS1, FASN, FADS2 | FDPS 697/4885GGPS1 7/4885PLA2G2C 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.